Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod dosing-interval study in new-onset generalized myasthenia gravis
ChiCTR2600133923Phase 4Completed
- Sponsor
- First Hospital of China Medical University
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of efgartigimod alfa in myasthenia gravis (MG) and generalized myasthenia gravis (gMG) (3 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Proportion of patients achieving minimal symptom expression by week 24. Started Oct 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on ChiCTR2600133923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133923.